Resumen

CANTUDO-CUENCA, MR; SANCHEZ-ARGAIZ, MC; CANTUDO-CUENCA, MD  y  MORA-MORA, MA. Pustular psoriasis with BRAF inhibitors to treat metastatic melanoma. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.1, pp.71-72.  Epub 18-Ene-2021. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2020000100018.

Targeted BRAF inhibition with vemurafenib and dabrafenib has proven to be a useful tool in the treatment of metastatic melanoma with BRAF-V600E mutation. While cutaneous adverse events are prevalent with BRAF inhibition, psoriasis is a rare complication. We report a case of palmoplantar pustular psoriasis in an adult man with metastatic melanoma treated with both BRAF inhibitors, sequentially. Systemic corticosteroids and apremilast were required to control symptomatology. To date, a case has been described in the literature of psoriasis associated with dabrafenib. We postulate that the elevation of tumor necrosis factor-alpha (TNF-a) and the paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway due to BRAF inhibition may be responsible for this case. More studies are needed to further elucidate the immunopathogenic mechanisms behind this adverse event.

Palabras clave : BRAF kinases; melanoma; psoriasis; drug related side effects and adverse reactions.

        · resumen en Español     · texto en Español     · Español ( pdf )